Advinus Gets Compensation from Merck (India)
This article was originally published in PharmAsia News
India-based Advinus Therapeutics received its first milestone payment from pharmaceutical giant Merck. The payment, for an undisclosed amount, was part of a partnership between the two companies initiated in November 2006. The initial agreement allowed Advinus to chose two of Merck's 10 research programs to develop drugs for metabolic problems including diabetes and obesity. The milestone payment was for research advances on two promising molecules that came three months ahead of schedule according to Advinus representatives. If these drugs continue to advance, Advinus will develop them until they reach Phase II clinical trials. At that point Merck will have the option of taking over for late-stage trials. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.